The purpose of this study is to determine whether OraVerse is safe and effective for the reversal of dental anesthesia in children 2 to 5 years of age weighing at least 10 kg.
This Phase 4 clinical study is designed as a multicenter, randomized, double-blinded, controlled study to evaluate the safety and efficacy of OraVerse in approximately 150 children 2 to 5 years of age. OraVerse or sham injection is administered at the completion of a dental procedure requiring local anesthesia with lidocaine 2% with 1:100,000 epinephrine. The dental procedure(s) comprising restoration/fillings shall be performed in a single quadrant of the mouth. The primary endpoint is safety and tolerability of OraVerse as measured by adverse events, vital signs, oral cavity assessments, nerve injury, and analgesics for intraoral pain. Secondary objectives in subjects 4 and 5 years of age include the safety and tolerability of OraVerse as measured by pain assessments using W-B PRS and evaluation of efficacy assessed by a pediatric Functional Assessment Battery (pFAB) and standardized lip and tongue palpation procedure.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
150
1.8mL dental cartridge delivered in doses of either 1/4, 1/2 or 1 cartridge depending on subject weight
No drug administered, simulation of injection used in same manner as drug
University of California, San Francisco
San Francisco, California, United States
Indiana University School of Dentistry
Indianapolis, Indiana, United States
Nationwide Children's Hospital
Columbus, Ohio, United States
University of Pennsylvania School of Dental
Philadelphia, Pennsylvania, United States
Incidence and severity of adverse events
Time frame: Up to 3 days
Clinically significant changes in vital signs
Blood pressure and pulse
Time frame: Up to 3 days
Clinically significant changes in oral cavity assessments
Time frame: Up to 3 days
Nerve injury
Time frame: Up to 3 days
Analgesics required for intraoral pain
Time frame: Up to 3 days
incidence, severity and duration of intraoral pain as measured by W-B PRS
Wong-Baker Pain Rating Scale used to assess subject pain
Time frame: Up to 3 days
Time to normal function
Measured by pediatric Functional Assessment Battery (pFAB) to determine when speaking, eating, drinking, drooling return to baseline
Time frame: Up to 3 days
Time to normal lip sensation
Measures time to normal lip and tongue sensation using standardized lip/tongue palpation procedure
Time frame: Up to 3 days
Time to normal tongue sensation
Measures time to normal tongue sensation using standardized lip/tongue palpation procedure
Time frame: Up to 3 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University of Pittsburgh School of Dental Medicine
Pittsburgh, Pennsylvania, United States
Jean Brown Research
Salt Lake City, Utah, United States
Center for Pediatric Dentistry
Seattle, Washington, United States